---
pmid: '28344315'
title: Proteomic characterization of human multiple myeloma bone marrow extracellular
  matrix.
authors:
- Glavey SV
- Naba A
- Manier S
- Clauser K
- Tahri S
- Park J
- Reagan MR
- Moschetta M
- Mishima Y
- Gambella M
- Rocci A
- Sacco A
- O'Dwyer ME
- Asara JM
- Palumbo A
- Roccaro AM
- Hynes RO
- Ghobrial IM
journal: Leukemia
year: '2017'
full_text_available: false
doi: 10.1038/leu.2017.102
---

# Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.
**Authors:** Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O'Dwyer ME, Asara JM, Palumbo A, Roccaro AM, Hynes RO, Ghobrial IM
**Journal:** Leukemia (2017)
**DOI:** [10.1038/leu.2017.102](https://doi.org/10.1038/leu.2017.102)

## Abstract

1. Leukemia. 2017 Nov;31(11):2426-2434. doi: 10.1038/leu.2017.102. Epub 2017 Mar 
27.

Proteomic characterization of human multiple myeloma bone marrow extracellular 
matrix.

Glavey SV(1)(2), Naba A(3), Manier S(1), Clauser K(4), Tahri S(1), Park J(1), 
Reagan MR(1), Moschetta M(1), Mishima Y(1), Gambella M(5), Rocci A(6), Sacco 
A(1)(7), O'Dwyer ME(2), Asara JM(8), Palumbo A(5), Roccaro AM(1)(7), Hynes 
RO(3)(9), Ghobrial IM(1).

Author information:
(1)Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
(2)Department of Hematology, National University of Ireland, Galway, Ireland.
(3)Koch Institute for Integrative Cancer Research, Massachusetts Institute of 
Technology, Cambridge, MA, USA.
(4)Protemics Platform, Broad Institute, Cambridge, MA, USA.
(5)University of Torino, Azienda Ospedaliero-Universitaria Citt√† della Salute e 
della Scienza di Torino, Torino, Italy.
(6)Manchester Royal Infirmary and Central Manchester University Hospital NHS 
Foundation, University of Manchester, Manchester, UK.
(7)SST Spedali Civili, Department Medical Oncology, CREA Laboratory, Brescia, 
Italy.
(8)Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 
USA.
(9)Howard Hughes Medical Institute, Massachusetts Institute of Technology, 
Cambridge, MA, USA.

The extracellular matrix (ECM) is a major component of the tumor 
microenvironment, contributing to the regulation of cell survival, 
proliferation, differentiation and metastasis. In multiple myeloma (MM), 
interactions between MM cells and the bone marrow (BM) microenvironment, 
including the BM ECM, are critical to the pathogenesis of the disease and the 
development of drug resistance. Nevertheless, composition of the ECM in MM and 
its role in supporting MM pathogenesis has not been reported. We have applied a 
novel proteomic-based strategy and defined the BM ECM composition in patients 
with monoclonal gammopathy of undetermined significance (MGUS), newly diagnosed 
and relapsed MM compared with healthy donor-derived BM ECM. In this study, we 
show that the tumor ECM is remodeled at the mRNA and protein levels in MGUS and 
MM to allow development of a permissive microenvironment. We further demonstrate 
that two ECM-affiliated proteins, ANXA2 and LGALS1, are more abundant in MM and 
high expression is associated with a decreased overall survival. This study 
points to the importance of ECM remodeling in MM and provides a novel proteomic 
pipeline for interrogating the role of the ECM in cancers with BM tropism.

DOI: 10.1038/leu.2017.102
PMID: 28344315 [Indexed for MEDLINE]
